UA103624C2 - Антитело, мишенью которого является полипептид baffr - Google Patents

Антитело, мишенью которого является полипептид baffr

Info

Publication number
UA103624C2
UA103624C2 UAA201100520A UAA201100520A UA103624C2 UA 103624 C2 UA103624 C2 UA 103624C2 UA A201100520 A UAA201100520 A UA A201100520A UA A201100520 A UAA201100520 A UA A201100520A UA 103624 C2 UA103624 C2 UA 103624C2
Authority
UA
Ukraine
Prior art keywords
antibodies
baffr
antibody
target
baffr polypeptide
Prior art date
Application number
UAA201100520A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристоф Хейссер
Юлия Нейгебауер
Эвелина Шадт
Стефани Урлингер
Максимилиан Войзетшлаегер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Priority claimed from PCT/EP2009/059030 external-priority patent/WO2010007082A1/en
Publication of UA103624C2 publication Critical patent/UA103624C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение касается антител, которые связываются с полипептидом BAFFR (SEQ ID NO: 87) со значением К, что составляет 100 нМ или меньше, и ингибируют пролиферацию человеческих В-клеток, которая индуцируется BLyS, со значением IC, которое составляет приблизительно 10 нМ или меньше, и истощают В-клеткиили
UAA201100520A 2008-07-17 2009-07-15 Антитело, мишенью которого является полипептид baffr UA103624C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
PCT/EP2009/059030 WO2010007082A1 (en) 2008-07-17 2009-07-15 Compositions and methods of use for therapeutic antibodies

Publications (1)

Publication Number Publication Date
UA103624C2 true UA103624C2 (ru) 2013-11-11

Family

ID=40104736

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100520A UA103624C2 (ru) 2008-07-17 2009-07-15 Антитело, мишенью которого является полипептид baffr

Country Status (3)

Country Link
US (3) US20160347851A1 (ru)
CO (1) CO6341571A2 (ru)
UA (1) UA103624C2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116294A1 (en) * 2017-12-15 2019-06-20 Creoptix Ltd. Assemblies and methods for screening sample fluids
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用

Also Published As

Publication number Publication date
CO6341571A2 (es) 2011-11-21
US20220298251A1 (en) 2022-09-22
US20160347851A1 (en) 2016-12-01
US20190135931A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
NZ590057A (en) Compositions and methods of use for therapeutic antibodies that bind a BAFFR polypeptide
EP2322557A3 (en) Compositions and methods for treating proliferative disorders
MX341884B (es) Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
MX346663B (es) Lineas de celulas de bajo nivel de fucosa y usos de las mismas.
EP2465922A3 (en) Mesenchymal stem cells expressing TNF-alpha receptor
MX356264B (es) Composiciones útiles como arenas sanitarias para animales.
EA201390666A1 (ru) Cxcr2-связывающие полипептиды
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
EA201590247A1 (ru) Антитела к siglec-15
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MY163057A (en) Means and methods for trating dlblcl
IN2012DN06588A (ru)
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2010120518A3 (en) Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EA200601517A1 (ru) Нацеливающие пиперидинилсодержащие соединения, селективно связывающие интегрины
MX357655B (es) Mediador soluble.
UA103624C2 (ru) Антитело, мишенью которого является полипептид baffr
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
EP2612906A3 (en) Derivation of embryonic stem cells and embryo-derived cells
WO2011115458A3 (ko) 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제
TN2010000599A1 (en) Compositions and methods of use for therapeutic antiodies
WO2021016079A3 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas